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Case Information
*Normal Range in Parentheses
Figure 1.  Virologic and Glycemic Response to Peg-IFN/RBV
•  To recognize that pegylated interferon/ribavirin (Peg-IFN/RBV) therapy for 
chronic hepatitis C (HCV) has been associated with the development of 
numerous autoimmune disorders, including type 1 diabetes.
•  Frequent blood glucose monitoring during Peg-IFN/RBV therapy is 
necessary, with investigation for decreased C-peptide levels and 
antibodies directed against pancreatic beta cells if hyperglycemia is 
persistent.
•  A 55 year old male with genotype 2b chronic HCV, occasional postprandial 
hyperglycemia, and a family history of type 2 diabetes presented to the 
emergency department after 17 weeks of pegylated interferon/ribavirin 
therapy with signs and symptoms of diabetic ketoacidosis (DKA).
•  In the preceding weeks, with the exception of mild fasting hyperglycemia, 
he had tolerated therapy well and had achieved a rapid virologic response 
(HCV RNA undetectable at week 4).  At the time fasting hyperglycemia 
was noted, the hemoglobin A1C was normal at 5.2%.
•  The patient subsequently developed weight loss, malaise, polyuria, and 
polydipsia. Upon arrival in the emergency department, his blood glucose 
was 846 mg/dL with positive urine ketones and serum acetone, and an 
elevated anion-gap metabolic acidosis consistent with DKA.
•  A diagnosis of new-onset type 1 diabetes was made due to low c-peptide 
levels and the presence of glutamic acid decarboxylase (GAD) antibodies. 
Peg-IFN/RBV therapy was discontinued and insulin therapy was initiated.
•  Despite premature discontinuation of Peg-IFN/RBV therapy, the patient 
achieved a sustained virologic response.
•  One year later, although C-peptide levels are in the low-normal range, he 
still requires insulin therapy.
Table 1.  Relevant Patient Data*
Discussion:
•  Chronic Hepatitis C, the most common blood-borne infection in the United 
States, can lead to hepatic fibrosis that can progress to cirrhosis. Peg-IFN/
RBV therapy has become the standard of care and typically cures >50% of 
those treated.
•  Numerous adverse effects are associated with Peg-IFN/RBV, many of 
which are autoimmune in etiology.  Such examples include various forms 
of inflammatory arthritis, a lupus-like syndrome, psoriasis, leukocytoclastic 
vasculitis, interstitial pneumonitis, autoimmune hemolytic anemia, immune 
thrombocytopenic purpura, a variety of thyroid disorders, autoimmune liver 
disease, and uncommonly, type 1 diabetes.
•  There have been several published case reports that associate new onset of 
diabetes with IFN therapy, which is often, insulin-requiring.
•  Alpha IFN have also been associated with the development, or exacerbation, 
of insulin resistance.  IFN therapy may stimulate a counter regulatory 
hormone secretion (i.e. growth hormone, glucagon), thus resulting in impaired 
glucose tolerance.
•  Alpha IFN may mediate destruction of pancreatic beta-cells by inducing 
inflammation and activation of T-helper lymphocytes along with over-
expression of MHC class I antigens in islet cells, leading to injury by CD8+ 
cytotoxic lymphocytes. This beta-cell injury may be permanent, as many 
affected patients require insulin for >1 year following cessation of peg-IFN/
ribavirin therapy.
•  Whereas we do not believe it is realistic to screen for every possible 
complication of IFN therapy, the potential for autoimmune disorders, 
including type 1 diabetes, needs to be discussed with prospective treatment 
candidates and incorporated into the risk-benefit analysis prior to therapy.
•  We recommend close laboratory monitoring in all patients undergoing peg-
IFN/ribavirin therapy.
•  The homeostasis model assessment (HOMA-IR) and quantitative insulin 
sensitivity check index (QUICKI) can be easily calculated to assess for insulin 
resistance in the setting of fasting hyperglycemia.
•  Persistently elevated blood glucose in patients receiving peg-IFN/ribavirin 
therapy could be a sign of beta cell injury. In these instances, we suggest 
prompt evaluation including GAD antibody and c-peptide assays to assess for 
the development of type 1 diabetes, which may have long-term implications.
Pre-Admission
      Fasting Blood Glucose 156 mg/dL (65-99 mg/dL)
      Hemoglobin A1C  5.2% (<7.0%)
      TSH 1.38 μIU/mL (0.35-4.0 μIU/mL) 
 On Admission
     Fasting Blood Glucose 846 mg/dL (65-99 mg/dL)
     Hemoglobin A1C  12.1% (<7.0%)
     Serum Acetone Positive (Negative)
     Anti-GAD Antibodies 29.7 nmol/L (<0.02 nmol/L)
     Serum C-peptide 0.3 ng/mL (0.9-6.9 ng/mL)
     TSH 0.96 μIU/mL (0.35-4.0 μIU/mL) 
Post-Admission
    Fasting Blood Glucose 221 mg/dL (65-99 mg/dL)
    Hemoglobin A1C  8.5% (<7.0%)
    Anti-GAD Antibodies 51.2 nmol/L (<0.02 nmol/L)
    Serum C-peptide 1.3 ng/mL (0.9-6.9 ng/mL)
    Fasting Insulin 9.3 (<29.2 μIU/mL)  
    TSH 1.84 μIU/mL (0.35-4.0 μIU/mL) 
    HOMA-IR 5.07 (<2.0)
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